Bevacizumab  	Bevacizumab  	 NNP	B-NP
in  	in  	 IN	O
combination  	combination  	 NN	O
with  	with  	 IN	O
a  	a  	 DT	O
taxane  	taxane  	 NN	B-NP
for  	for  	 IN	I-NP
the  	the  	 DT	I-NP
first-line  	first-line  	 JJ	I-NP
treatment  	treatment  	 NN	I-NP
of  	of  	 IN	I-NP
HER2-negative  	HER2-negative  	 CD	I-NP
metastatic  	metastatic  	 JJ	I-NP
breast  	breast  	 NN	I-NP
cancer  	cancer  	 NN	I-NP
This  	This  	 DT	O
paper  	paper  	 NN	O
presents  	presents  	 VBZ	O
a  	a  	 DT	O
summary  	summary  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
evidence  	evidence  	 NN	B-NP
review  	review  	 NN	I-NP
group  	group  	 NN	I-NP
( 	( 	 -LRB-	O
ERG 	ERG 	 NNP	O
)  	)  	 -RRB-	O
report  	report  	 NN	O
into  	into  	 IN	O
the  	the  	 DT	O
use  	use  	 NN	O
of  	of  	 IN	O
bevacizumab  	bevacizumab  	 NNS	B-NP
( 	( 	 -LRB-	O
Avastin® 	Avastin® 	 NNP	B-NP
,  	,  	 ,	O
Roche 	Roche 	 NNP	O
)  	)  	 -RRB-	O
in  	in  	 IN	O
combination  	combination  	 NN	O
with  	with  	 IN	O
a  	a  	 DT	O
taxane  	taxane  	 NN	B-NP
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
untreated  	untreated  	 JJ	O
metastatic  	metastatic  	 JJ	B-NP
breast  	breast  	 NN	I-NP
cancer  	cancer  	 NN	I-NP
( 	( 	 -LRB-	O
mBC 	mBC 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
main  	main  	 JJ	O
clinical  	clinical  	 JJ	B-NP
effectiveness  	effectiveness  	 NN	I-NP
data  	data  	 NNS	I-NP
were  	were  	 VBD	O
derived  	derived  	 VBN	O
from  	from  	 IN	O
a  	a  	 DT	O
single 	single 	 JJ	O
,  	,  	 ,	O
open-label  	open-label  	 JJ	B-NP
randomised  	randomised  	 NNS	O
controlled  	controlled  	 VBN	B-NP
trial  	trial  	 NN	I-NP
( 	( 	 -LRB-	O
RCT 	RCT 	 NNP	B-NP
)  	)  	 -RRB-	O
( 	( 	 -LRB-	O
E2100 	E2100 	 NNP	O
)  	)  	 -RRB-	O
that  	that  	 WDT	O
evaluated  	evaluated  	 VBD	O
the  	the  	 DT	O
addition  	addition  	 NN	B-NP
of  	of  	 IN	O
bevacizumab  	bevacizumab  	 VBG	O
to  	to  	 TO	O
weekly  	weekly  	 JJ	O
( 	( 	 -LRB-	O
q.w. 	q.w. 	 NNP	O
)  	)  	 -RRB-	O
paclitaxel  	paclitaxel  	 NN	B-NP
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
human  	human  	 JJ	O
epidermal  	epidermal  	 JJ	B-NP
growth  	growth  	 NN	I-NP
factor  	factor  	 NN	I-NP
receptor  	receptor  	 NN	I-NP
2-negative  	2-negative  	 CD	O
mBC  	mBC  	 NNS	B-NP
who  	who  	 WP	O
had  	had  	 VBD	O
not  	not  	 RB	O
previously  	previously  	 RB	O
received  	received  	 VBD	O
chemotherapy  	chemotherapy  	 VBN	O
for  	for  	 IN	O
advanced  	advanced  	 JJ	O
disease 	disease 	 NN	O
.  	.  	 .	O
This  	This  	 DT	O
trial  	trial  	 NN	O
reported  	reported  	 VBD	O
statistically  	statistically  	 RB	O
significant  	significant  	 JJ	O
increases  	increases  	 NNS	O
in  	in  	 IN	O
median  	median  	 JJ	B-NP
progression-free  	progression-free  	 JJ	I-NP
survival  	survival  	 NN	I-NP
( 	( 	 -LRB-	O
PFS 	PFS 	 NNP	B-NP
)  	)  	 -RRB-	O
for  	for  	 IN	O
the  	the  	 DT	O
addition  	addition  	 NN	B-NP
of  	of  	 IN	I-NP
bevacizumab  	bevacizumab  	 NNS	I-NP
( 	( 	 -LRB-	O
5.8-11.3  	5.8-11.3  	 CD	O
months 	months 	 NNS	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Median  	Median  	 JJ	B-NP
overall  	overall  	 JJ	O
survival  	survival  	 NN	O
was  	was  	 VBD	O
not  	not  	 RB	O
significantly  	significantly  	 RB	O
different  	different  	 JJ	O
between  	between  	 IN	O
the  	the  	 DT	O
two  	two  	 CD	O
groups 	groups 	 NNS	O
;  	;  	 :	O
whether  	whether  	 IN	O
this  	this  	 DT	O
is  	is  	 VBZ	O
a  	a  	 DT	O
true  	true  	 JJ	O
null  	null  	 JJ	O
finding  	finding  	 NN	O
or  	or  	 CC	O
due  	due  	 JJ	O
to  	to  	 TO	O
crossover  	crossover  	 VB	O
between  	between  	 IN	O
treatment  	treatment  	 NN	B-NP
arms  	arms  	 NNS	I-NP
cannot  	cannot  	 RB	O
be  	be  	 VB	O
established 	established 	 VBN	O
,  	,  	 ,	O
as  	as  	 IN	O
relevant  	relevant  	 JJ	O
data  	data  	 NNS	O
were  	were  	 VBD	O
not  	not  	 RB	O
collected 	collected 	 VBN	O
.  	.  	 .	O
The  	The  	 DT	O
manufacturer  	manufacturer  	 NN	B-NP
reported  	reported  	 VBD	O
that  	that  	 IN	O
the  	the  	 DT	O
addition  	addition  	 NN	B-NP
of  	of  	 IN	O
bevacizumab  	bevacizumab  	 VBG	O
to  	to  	 TO	O
paclitaxel  	paclitaxel  	 CD	B-NP
q.w.  	q.w.  	 CD	I-NP
therapy  	therapy  	 NN	O
was  	was  	 VBD	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
a  	a  	 DT	O
significant  	significant  	 JJ	O
improvement  	improvement  	 NN	O
in  	in  	 IN	O
quality  	quality  	 NN	O
of  	of  	 IN	O
life 	life 	 NN	O
,  	,  	 ,	O
as  	as  	 RB	O
measured  	measured  	 VBN	O
by  	by  	 IN	O
FACT-B  	FACT-B  	 NNP	B-NP
( 	( 	 -LRB-	O
functional  	functional  	 JJ	B-NP
assessment  	assessment  	 NN	I-NP
of  	of  	 IN	I-NP
cancer  	cancer  	 NN	I-NP
therapy  	therapy  	 NN	I-NP
for  	for  	 IN	I-NP
breast  	breast  	 JJ	I-NP
cancer 	cancer 	 NN	O
)  	)  	 -RRB-	O
scores 	scores 	 NNS	O
.  	.  	 .	O
However 	However 	 RB	O
,  	,  	 ,	O
the  	the  	 DT	O
ERG  	ERG  	 NNP	O
noted  	noted  	 VBD	O
that  	that  	 IN	O
these  	these  	 DT	O
results  	results  	 NNS	O
were  	were  	 VBD	O
based  	based  	 VBN	O
on  	on  	 IN	O
extreme  	extreme  	 JJ	O
imputed  	imputed  	 JJ	O
values 	values 	 NNS	O
,  	,  	 ,	O
the  	the  	 DT	O
removal  	removal  	 NN	O
of  	of  	 IN	O
which  	which  	 WDT	O
led  	led  	 VBD	O
to  	to  	 TO	O
non-significant  	non-significant  	 JJ	B-NP
differences  	differences  	 NNS	I-NP
in  	in  	 IN	O
quality  	quality  	 NN	O
of  	of  	 IN	O
life 	life 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
manufacturer  	manufacturer  	 NN	B-NP
conducted  	conducted  	 VBD	O
an  	an  	 DT	O
indirect  	indirect  	 JJ	O
comparison 	comparison 	 NN	O
.  	.  	 .	O
However 	However 	 RB	O
,  	,  	 ,	O
owing  	owing  	 VBG	O
to  	to  	 TO	O
methodological  	methodological  	 VB	B-NP
limitations  	limitations  	 NNS	I-NP
and  	and  	 CC	O
concerns  	concerns  	 NNS	O
about  	about  	 IN	O
the  	the  	 DT	O
validity  	validity  	 NN	O
and  	and  	 CC	O
exchangeability  	exchangeability  	 NN	B-NP
of  	of  	 IN	O
the  	the  	 DT	O
included  	included  	 JJ	O
trials 	trials 	 NNS	O
,  	,  	 ,	O
the  	the  	 DT	O
ERG  	ERG  	 NNP	O
did  	did  	 VBD	O
not  	not  	 RB	O
consider  	consider  	 VB	O
the  	the  	 DT	O
findings  	findings  	 NNS	O
to  	to  	 TO	O
be  	be  	 VB	O
reliable 	reliable 	 JJ	O
.  	.  	 .	O
One  	One  	 CD	O
additional  	additional  	 JJ	O
relevant  	relevant  	 JJ	O
RCT  	RCT  	 NNP	B-NP
[ 	[ 	 -LRB-	O
AVADO  	AVADO  	 NNP	B-NP
( 	( 	 -LRB-	O
Avastin  	Avastin  	 NNP	B-NP
and  	and  	 CC	O
Docetaxel 	Docetaxel 	 NNP	B-NP
) 	) 	 -RRB-	O
;  	;  	 :	O
BO17708 	BO17708 	 CD	O
]  	]  	 -RRB-	O
evaluating  	evaluating  	 VBG	O
the  	the  	 DT	O
addition  	addition  	 NN	B-NP
of  	of  	 IN	O
bevacizumab  	bevacizumab  	 VBG	O
to  	to  	 TO	O
docetaxel  	docetaxel  	 NNS	B-NP
was  	was  	 VBD	O
excluded  	excluded  	 VBN	O
from  	from  	 IN	O
the  	the  	 DT	O
manufacturer 	manufacturer 	 NN	O
's  	's  	 POS	O
submission 	submission 	 NN	O
.  	.  	 .	O
This  	This  	 DT	O
was  	was  	 VBD	O
summarised  	summarised  	 VBN	O
by  	by  	 IN	O
the  	the  	 DT	O
ERG 	ERG 	 NNP	O
.  	.  	 .	O
In  	In  	 IN	O
terms  	terms  	 NNS	O
of  	of  	 IN	O
response  	response  	 NN	B-NP
rate  	rate  	 NN	I-NP
and  	and  	 CC	O
PFS 	PFS 	 NNP	B-NP
,  	,  	 ,	O
AVADO  	AVADO  	 NNP	B-NP
reported  	reported  	 VBD	O
a  	a  	 DT	O
markedly  	markedly  	 RB	O
smaller  	smaller  	 JJR	O
benefit  	benefit  	 NN	O
of  	of  	 IN	O
adding  	adding  	 VBG	B-NP
bevacizumab  	bevacizumab  	 NN	I-NP
to  	to  	 TO	O
docetaxel  	docetaxel  	 VB	O
than  	than  	 IN	O
that  	that  	 WDT	O
reported  	reported  	 VBD	O
for  	for  	 IN	O
adding  	adding  	 VBG	B-NP
bevacizumab  	bevacizumab  	 NN	I-NP
to  	to  	 TO	O
q.w.  	q.w.  	 CD	B-NP
paclitaxel  	paclitaxel  	 NN	O
in  	in  	 IN	O
E2100 	E2100 	 CD	O
.  	.  	 .	O
AVADO  	AVADO  	 NNP	B-NP
also  	also  	 RB	O
reported  	reported  	 VBD	O
no  	no  	 DT	O
statistically  	statistically  	 JJ	O
significant  	significant  	 JJ	O
effect  	effect  	 NN	O
of  	of  	 IN	O
combination  	combination  	 NN	B-NP
therapy  	therapy  	 NN	I-NP
versus  	versus  	 IN	O
docetaxel  	docetaxel  	 NN	B-NP
in  	in  	 IN	O
terms  	terms  	 NNS	O
of  	of  	 IN	O
overall  	overall  	 JJ	O
survival 	survival 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
manufacturer  	manufacturer  	 NN	B-NP
developed  	developed  	 VBD	O
a  	a  	 DT	O
de  	de  	 FW	B-NP
novo  	novo  	 FW	I-NP
economic  	economic  	 JJ	I-NP
model  	model  	 NN	I-NP
that  	that  	 IN	O
considered  	considered  	 VBN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
the  	the  	 DT	O
same  	same  	 JJ	O
baseline  	baseline  	 NN	B-NP
characteristics  	characteristics  	 NNS	I-NP
as  	as  	 IN	O
women  	women  	 NNS	O
in  	in  	 IN	O
the  	the  	 DT	O
E2100  	E2100  	 JJ	B-NP
trial 	trial 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
model  	model  	 NN	O
assessed  	assessed  	 VBD	B-NP
BEV  	BEV  	 NNP	I-NP
+  	+  	 NNP	O
PAC  	PAC  	 NNP	O
-  	-  	 :	O
bevacizumab  	bevacizumab  	 CD	B-NP
10  	10  	 CD	O
mg 	mg 	 CD	B-NP
/ 	/ 	 CD	I-NP
kg  	kg  	 CD	I-NP
every  	every  	 DT	O
2  	2  	 CD	O
weeks  	weeks  	 NNS	O
in  	in  	 IN	O
combination  	combination  	 NN	O
with  	with  	 IN	O
paclitaxel  	paclitaxel  	 CD	B-NP
90  	90  	 CD	O
mg 	mg 	 CD	B-NP
/ 	/ 	 CD	O
m2  	m2  	 CD	O
weekly  	weekly  	 JJ	O
for  	for  	 IN	O
3  	3  	 CD	O
weeks  	weeks  	 NNS	O
followed  	followed  	 VBN	O
by  	by  	 IN	O
1  	1  	 CD	O
week  	week  	 NN	B-NP
of  	of  	 IN	O
rest 	rest 	 NN	O
;  	;  	 :	O
PAC  	PAC  	 NNP	B-NP
q.w.  	q.w.  	 NNP	I-NP
-  	-  	 :	O
paclitaxel  	paclitaxel  	 CD	B-NP
( 	( 	 -LRB-	O
monotherapy 	monotherapy 	 LS	B-NP
)  	)  	 -RRB-	O
90  	90  	 CD	O
mg 	mg 	 CD	B-NP
/ 	/ 	 CD	O
m2  	m2  	 CD	O
weekly  	weekly  	 JJ	O
for  	for  	 IN	O
3  	3  	 CD	O
weeks  	weeks  	 NNS	O
followed  	followed  	 VBN	O
by  	by  	 IN	O
1  	1  	 CD	O
week  	week  	 NN	B-NP
of  	of  	 IN	O
rest 	rest 	 NN	O
;  	;  	 :	O
DOC  	DOC  	 NNP	B-NP
-  	-  	 :	O
docetaxel  	docetaxel  	 CD	B-NP
( 	( 	 -LRB-	O
monotherapy 	monotherapy 	 LS	B-NP
)  	)  	 -RRB-	O
75  	75  	 CD	O
mg 	mg 	 CD	B-NP
/ 	/ 	 CD	O
m2  	m2  	 CD	O
on  	on  	 IN	O
day  	day  	 NN	O
1  	1  	 CD	O
every  	every  	 DT	O
21  	21  	 CD	O
days  	days  	 NNS	O
( 	( 	 -LRB-	O
considered  	considered  	 VBN	O
current  	current  	 JJ	O
UK  	UK  	 NNP	B-NP
NHS  	NHS  	 NNP	I-NP
clinical  	clinical  	 JJ	I-NP
practice  	practice  	 NN	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
submission 	submission 	 NN	O
) 	) 	 -RRB-	O
;  	;  	 :	O
and  	and  	 CC	O
GEM  	GEM  	 NNP	O
+  	+  	 NNP	O
PAC  	PAC  	 NNP	O
-  	-  	 :	O
gemcitabine  	gemcitabine  	 CD	B-NP
1250  	1250  	 CD	O
mg 	mg 	 CD	B-NP
/ 	/ 	 CD	O
m2  	m2  	 CD	O
on  	on  	 IN	O
days  	days  	 NNS	O
1  	1  	 CD	O
and  	and  	 CC	O
8  	8  	 CD	O
plus  	plus  	 CC	O
paclitaxel  	paclitaxel  	 CD	B-NP
175  	175  	 CD	O
mg 	mg 	 CD	B-NP
/ 	/ 	 CD	O
m2  	m2  	 CD	O
on  	on  	 IN	O
day  	day  	 NN	O
1  	1  	 CD	O
every  	every  	 DT	O
21  	21  	 CD	O
days 	days 	 NNS	O
.  	.  	 .	O
Pairwise  	Pairwise  	 JJ	B-NP
comparisons  	comparisons  	 NNS	I-NP
were  	were  	 VBD	O
made  	made  	 VBN	O
between  	between  	 IN	O
BEV  	BEV  	 NNP	B-NP
+  	+  	 NNP	O
PAC  	PAC  	 NNP	O
and  	and  	 CC	O
PAC  	PAC  	 NNP	O
( 	( 	 -LRB-	O
using  	using  	 VBG	O
the  	the  	 DT	O
E2100  	E2100  	 JJ	B-NP
trial 	trial 	 NN	I-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
BEV  	BEV  	 NNP	B-NP
+  	+  	 NNP	O
PAC  	PAC  	 NNP	O
and  	and  	 CC	O
DOC 	DOC 	 NNP	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
BEV  	BEV  	 NNP	B-NP
+  	+  	 NNP	O
PAC  	PAC  	 NNP	O
and  	and  	 CC	O
GEM  	GEM  	 NNP	O
+  	+  	 NNP	O
PAC 	PAC 	 NNP	O
.  	.  	 .	O
Based  	Based  	 VBN	O
on  	on  	 IN	O
NHS  	NHS  	 NNP	B-NP
list  	list  	 NN	I-NP
prices 	prices 	 NNS	I-NP
,  	,  	 ,	O
the  	the  	 DT	O
manufacturer 	manufacturer 	 NN	O
's  	's  	 POS	O
model  	model  	 NN	O
estimated  	estimated  	 VBD	O
incremental  	incremental  	 JJ	B-NP
cost-effectiveness  	cost-effectiveness  	 JJ	I-NP
ratios  	ratios  	 NNS	I-NP
( 	( 	 -LRB-	O
ICERs 	ICERs 	 NNP	B-NP
)  	)  	 -RRB-	O
for  	for  	 IN	O
BEV  	BEV  	 NNP	B-NP
+  	+  	 NNP	O
PAC  	PAC  	 NNP	O
of  	of  	 IN	O
£  	£  	 CD	O
117,803 	117,803 	 CD	O
,  	,  	 ,	O
£  	£  	 NNP	O
115,059  	115,059  	 NNP	O
and  	and  	 CC	O
£  	£  	 CD	O
105,777  	105,777  	 CD	O
per  	per  	 IN	O
QALY  	QALY  	 NNP	B-NP
gained 	gained 	 VBD	O
,  	,  	 ,	O
relative  	relative  	 JJ	O
to  	to  	 TO	O
PAC 	PAC 	 NNP	O
,  	,  	 ,	O
DOC  	DOC  	 NNP	B-NP
and  	and  	 CC	O
GEM  	GEM  	 NNP	O
+  	+  	 NNP	O
PAC  	PAC  	 NNP	O
regimens 	regimens 	 NN	O
,  	,  	 ,	O
respectively 	respectively 	 RB	O
.  	.  	 .	O
If  	If  	 IN	O
the  	the  	 DT	O
NHS  	NHS  	 NNP	B-NP
Purchasing  	Purchasing  	 NNP	O
and  	and  	 CC	O
Supply  	Supply  	 NNP	B-NP
Agency  	Agency  	 NNP	I-NP
prices  	prices  	 NNS	I-NP
for  	for  	 IN	O
PAC  	PAC  	 NNP	O
with  	with  	 IN	O
a  	a  	 DT	O
10-g  	10-g  	 JJ	O
cap  	cap  	 NN	O
on  	on  	 IN	O
the  	the  	 DT	O
cost  	cost  	 NN	O
per  	per  	 IN	O
patient  	patient  	 NN	O
of  	of  	 IN	O
BEV  	BEV  	 NNP	B-NP
were  	were  	 VBD	O
used  	used  	 VBN	O
instead 	instead 	 RB	O
,  	,  	 ,	O
the  	the  	 DT	O
ICERs  	ICERs  	 JJ	O
for  	for  	 IN	O
BEV  	BEV  	 NNP	B-NP
+  	+  	 NNP	O
PAC  	PAC  	 NNP	O
were  	were  	 VBD	O
estimated  	estimated  	 VBN	O
at  	at  	 IN	O
£  	£  	 CD	O
77,314 	77,314 	 CD	O
,  	,  	 ,	O
£  	£  	 NNP	O
57,753  	57,753  	 NNP	O
and  	and  	 CC	O
£  	£  	 CD	O
60,101  	60,101  	 CD	O
per  	per  	 IN	O
QALY 	QALY 	 NNP	B-NP
,  	,  	 ,	O
respectively 	respectively 	 RB	O
.  	.  	 .	O
The  	The  	 DT	O
submission  	submission  	 NN	O
suggested  	suggested  	 VBD	O
that  	that  	 IN	O
the  	the  	 DT	O
regimen  	regimen  	 NN	O
of  	of  	 IN	O
BEV  	BEV  	 NNP	B-NP
+  	+  	 NNP	O
DOC  	DOC  	 NNP	B-NP
is  	is  	 VBZ	O
not  	not  	 RB	O
cost-effective  	cost-effective  	 JJ	O
because  	because  	 IN	O
it  	it  	 PRP	O
is  	is  	 VBZ	O
considered  	considered  	 VBN	O
less  	less  	 RBR	O
effective  	effective  	 JJ	O
and  	and  	 CC	O
more  	more  	 RBR	O
costly  	costly  	 JJ	O
than  	than  	 IN	O
BEV  	BEV  	 NNP	B-NP
+  	+  	 NNP	O
PAC 	PAC 	 NNP	O
.  	.  	 .	O
Analysis  	Analysis  	 NN	O
by  	by  	 IN	O
the  	the  	 DT	O
ERG  	ERG  	 NNP	O
suggested  	suggested  	 VBD	O
that  	that  	 DT	O
alternative  	alternative  	 JJ	O
assumptions  	assumptions  	 NNS	O
can  	can  	 MD	O
increase  	increase  	 VB	O
the  	the  	 DT	O
ICERs  	ICERs  	 JJ	O
further  	further  	 JJ	O
and 	and 	 CC	O
,  	,  	 ,	O
based  	based  	 VBN	O
on  	on  	 IN	O
current  	current  	 JJ	O
prices 	prices 	 NNS	O
,  	,  	 ,	O
no  	no  	 DT	O
plausible  	plausible  	 JJ	O
changes  	changes  	 NNS	O
to  	to  	 TO	O
the  	the  	 DT	O
model  	model  	 NN	B-NP
assumptions  	assumptions  	 NNS	I-NP
will  	will  	 MD	O
bring  	bring  	 VB	O
the  	the  	 DT	O
ICERs  	ICERs  	 JJ	O
for  	for  	 IN	O
BEV  	BEV  	 NNP	B-NP
+  	+  	 NNP	O
PAC  	PAC  	 NNP	O
lower 	lower 	 RBR	O
.  	.  	 .	O
